Research Article

The Impact of the Coexpression of MET and ESR Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC Dataset

Table 1

MET, ESR1, and ESR2 mRNA expressions in patients with breast cancer.

CharacteristicsMean ± SD (range)

MET mRNA expression log intensity5.61 ± 0.29 (4.96–7.86)
ESR1 mRNA expression log intensity9.61 ± 2.13 (5.22–13.27)
ESR2 mRNA expression log intensity5.44 ± 0.15 (4.90–6.28)

Characteristicsn (%)

MET mRNA
 Low1087 (57.1)
 High817 (42.9)
ESR1 mRNA
 Low713 (37.4)
 High1191 (62.6)
ESR2 mRNA
 Low986 (51.8)
 High918 (48.2)
MET/ESR coexpression status
299 (15.7)
786 (41.3)
416 (21.8)
403 (21.2)
591 (31.0)
498 (26.2)
363 (19.1)
452 (23.7)

Patients with mRNA gene expression equal to or below the mean value were indicated to have “low” expression status, while those with mRNA log intensity greater than the mean value were set to have “high” expression status. n(%); frequency and valid percentage.